In the context of rheumatoid arthritis, atopic dermatitis, and IBD, the administration of IRT5 increased the levels of IL-10, TGF-β, and IDO in DCs, leading to the induction of Tregs139. The gene discussed is TGFB1; the disease is rheumatoid arthritis.